| Friday, November 15, 2024 |
|
| A Brief History of Psychedelics |
Franklin King, MD |
| Pharmacology |
Franklin King, MD |
| Keynote: Psychedelic-Assisted Therapy: a 21st Century Approach to Mental Health? |
Rick Doblin, MD |
| Background, Pharmacology, & Keynote Question & Answer |
Jerrold F. Rosenbaum, MD; Rick Doblin, PhD |
| From Efficacy to Effectiveness: Towards Reliable Evidence-Based Policy for Psychedelic Therapies |
Eduardo Schenberg, PhD |
| Risks and Harms in Psychedelics and Psychedelic-Assisted Therapies |
Alden Doerner Rinaldi, MD |
| A Theological Reckoning with Bad Trips: A Patient’s Perspective |
Rachel Peterson, Mdiv |
| Risks, Harms and Conceptual Challenges Panel Discussion |
Franklin King, MD; Rachel Peterson, Mdiv; Alden Doerner Rinaldi, MD; Eduardo Schenberg, PhD |
| Psychedelic-Assisted Therapies and Serious Medical Illness |
Roxanne Sholevar, MD, Zachary Sager, MD, Yvan Beaussant, MD |
| Psilocybin in Functional Medical Disorders: A Pilot Study in Irritable Bowel Syndrome |
Erin Mauney, MD; Franklin King, MD |
| Psychedelics & Psychosomatics Panel Discussion |
Jerrold F. Rosenbaum, MD; Erin Mauney, MD; Roxanne Sholevar, MD; Zachary Sager, MD; Yvan Beaussant, MD; Franklin King, MD |
| Reflections from Psychedelic-Assisted Psychotherapy Using Ketamine and MDMA |
Elizabeth Call, PhD |
| What’s Therapy Got to Do With It? |
Michael Alpert, MD |
| Music and Your Mind: Approach to Music in Psychedelic Therapy Sessions |
Lisa Summer, PhD |
| Psychedelic-Assisted Psychotherapy Panel Discussion |
Franklin King, MD; Elizabeth Call, PhD; Michael Alpert, MD; Lisa Summer, PhD |
| The Neurobiology of Plant Medicine: Leveraging 21st Century Approaches to Ethnobotany |
Stephen Haggarty, PhD |
| Psychedelics and Psychosis: Phenomenological Differences and Overlaps |
Haley Maria Dourron, PhD |
| Decolonizing the Medicalization of Psychedelics |
Christine Hauskeller, PhD |
| Saturday, November 16, 2024 |
|
| Simultaneous Imaging of Clinicians and Participants with Fibromyalgia: Perspectives and Results from the MDMA Hyperscan Study |
Vitaly Napadow, PhD |
| The Effects of Psilocybin on Cognition |
Ceyda Sayali, PhD |
| Cognitive Neuroscience of Psychedelics |
Alfred Kaye, MD, PhD |
| Neuroscience of Psychedelics Panel Discussion |
Bruce Rosen, MD, PhD; Ceyda Sayali, PhD; Alfred Kaye, MD, PhD; Vitaly Napadow, PhD |
| Ketamine-Assisted Psychotherapy – Inpatient Treatment of the Future? |
Fernando Espi Forcen, MD |
| Ketamine and Esketamine for Major Depression |
Cristina Cusin, MD |
| Ketamine Panel Discussion |
Franklin King, MD; Cristina Cusin, MD; Fernando Espi Forcen, MD |
| Psilocybin-Assisted Therapy for Depression: A Critical Look at the Evidence |
Kelley O’Donnell, MD |
| Amplifying PTSD Treatments with MDMA |
Anne Wagner, PhD |
| Psychedelics and Addictions: Psilocybin for Cocaine Use Disorder |
Brian Barnett, MD |
| Clinical Applications of Psychedelics Panel Discussion |
Franklin King, MD; Kelley O’Donnell, MD; Anne Wagner, PhD; Brian Barnett, MD |
| Challenging Structural Racism in Psychedelic Research |
Darron Smith, PhD |
| Psychedelics and the Law |
Mason Marks, MD, JD |
| Structural and Systemic Issues in Psychedelics Panel Discussion |
Franklin King, MD; Mason Marks, MD, JD; Darron Smith, PhD |
| How to Educate Clinicians on Psychedelics? |
Janis Phelps, PhD, Franklin King, MD, Roxanne Sholevar, MD |
| Who’s Going to Pay for All This? Challenges of Psychedelic Rollout in Hospital Psychiatry |
Brian Barnett, MD |
| Challenges of Implementation Panel Discussion |
Franklin King, MD; Janis Phelps, PhD; Brian Barnett, MD; Roxanne Sholevar, MD |
